Fig. 6
SAA1 peptides including the COOH terminal PNHFRPAGLPEKY peptide versus all other more NH2 terminal peptides. a D/PNHFRPAGLPEKY quantile plot. b D/PNHFRPAGLPEKY intensity box plot. c SAA1 amino terminal peptide FFGHGAEDSLADQAANEWG quantile plot. d SAA1 amino terminal peptide FFGHGAEDSLADQAANEWG box plot. e SAA1 amino terminal grouped peptide FFGHGAEDSLADQAANEWG, RSFFSFLGEAFDGAR & YFHARGNYDAAKR quantile plot. f SAA1 amino terminal grouped peptide FFGHGAEDSLADQAANEWG, RSFFSFLGEAFDGAR and YFHARGNYDAAKR box plot. Treatment ID numbers: 1, Alzheimer normal; 2, Alzheimer’s normal control STYP; 3, Alzheimer’s dementia; 4, Alzheimer’s dementia STYP; 5, Cancer breast; 6, Cancer breast STYP; 7, Cancer control; 8, Cancer control STYP; 9, Cancer ovarian; 10, Cancer ovarian STYP; 11, Ice Cold; 12, Ice Cold STYP; 13, Heart attack Arterial; 14, Heart attack Arterial STYP; 15, Heart attack normal control, 16, Heart attack normal Control STYP; 17, Heart attack; 18, Heart attack STYP; 19, Multiple Sclerosis normal control; 20, Multiple Sclerosis normal control STYP; 21, Multiple sclerosis; 22, Multiple sclerosis STYP, 23, Sepsis; 24, Sepsis STYP; 25, Sepsis normal control; 26, Sepsis normal control STYP. There was significant effects of treatments and peptides by two-way ANOVA